GLP-1 medications are transforming how we think about chronic disease, yet up to 60% of patients quit within the first year. In this fireside chat with Sky News' David Rhodes, eMed CEO Linda Yaccarino makes the case that GLP-1s are not a weight loss story, they're a preventative care story. From groundbreaking new data on GLP-1 outcomes in women to the role employers must play in closing the access and adherence gap, this session brings an urgent, unfiltered perspective on what's broken in healthcare and what it looks like when it actually works.
Truman Brewery (SXSW London Stage)
June 2, 2026, 12:40 - 1:10 PM